• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2016 Fiscal Year Final Research Report

Development of a novel RNA trans-splicing molecule for cancer gene therapy targeting to cancer-type organic anion transporting polypeptide 1B3

Research Project

  • PDF
Project/Area Number 15K14994
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Medical pharmacy
Research InstitutionChiba University

Principal Investigator

Furihata Tomomi  千葉大学, 大学院医学研究院, 助教 (80401008)

Project Period (FY) 2015-04-01 – 2017-03-31
Keywordscancer-type OATP1B3 / がん遺伝子治療 / がん
Outline of Final Research Achievements

Spliceosome-mediated RNA trans-splicing, which is mediated by an RNA trans-splicing molecule (RTM), is expected to be a promising tool for cancer gene therapy. RTM leads to trans-splicing between a target mRNA and a suicide gene (such as the herpes simplex virus thymidine kinase) to generate the suicide protein. Therefore, we aimed at development and characterization of an RTM targeting to Ct-OATP1B3 mRNA (hereafter referred to as RTM44-2), which is expressed in various cancer tissues in a cancer-specific manner. To examine the RTM44-2 functionality, we developed LS180 cells stably expressing RTM44-2 (RTM/LS), and cytotoxic assays were performed using ganciclovir (GCV). As a result. GCV significantly reduced the viability of RTM/LS cells. Furthermore, such anti-cancer effects of the RTM-GCV system was also observed in vivo xenograft models. To summarize, our results indicate that the Ct-OATP1B3-targeted gene therapy has a potential to become an effective anti-cancer therapy.

Free Research Field

薬理学・薬物動態学

URL: 

Published: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi